Masterflex SE has achieved its forecast for the 2025 financial year according to preliminary figures, posting new record earnings while strengthening its financial position. The company reported consolidated revenue of EUR 102.6 million, exceeding the previous year's level of EUR 98.1 million by 4.6% and falling within the forecast range of EUR 100 million to EUR 105 million. This performance occurred despite what the company described as a continuing challenging economic environment.
The operational performance developed positively, with the US subgroup performing particularly well in 2025. The medical technology area experienced dynamic demand growth, increasing its share of consolidated revenue from 18% in 2024 to 21% in the 2025 financial year. Despite economic headwinds particularly noticeable in Germany, demand in the industrial customer sectors grouped under "Tech" and in the trading business declined only moderately. The order backlog remained stable at EUR 19.8 million at year-end, in line with the previous year's level.
Masterflex recorded a 7.4% increase in operating EBITDA to EUR 19.5 million compared to EUR 18.2 million in the previous year. Operating EBIT rose by 9.8% to EUR 14.0 million from EUR 12.7 million, also marking a new record. Despite currency losses and start-up costs for the new site in Morocco, the operating EBIT margin increased to 13.6% compared with 13.0% in the previous year. EBIT reached EUR 13.7 million, within the forecast range of EUR 12 million to EUR 15 million and up from EUR 12.5 million in the previous year.
The company significantly strengthened its financial position, with the equity ratio increasing to 73.3% from 67.7% in the previous year. Financial liabilities were substantially reduced, with net debt falling to EUR 2.7 million from EUR 9.0 million in the previous year. The debt ratio improved significantly to 0.1 from 0.5 in the previous year. Dr Andreas Bastin, CEO of Masterflex SE, commented on the results, stating the company met its forecasts, achieved solid revenue growth, and slightly increased profitability thanks to continuous efficiency improvements.
The development of the medical technology business and further strengthening of the balance sheet were particularly noted as positive developments. Bastin indicated that building on this solid foundation positions the company well to continue its growth course in coming years. The figures remain subject to confirmation by auditors and approval by the Supervisory Board, with the 2025 consolidated financial statements and 2026 forecast scheduled for publication on March 31, 2026. Additional information about the company is available at https://www.crossalliance.de.
